drug

Midazolam

MeSH D008874

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by Amgen

2 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Schizophrenia or Schizoaffective Disorder Depression Psychosomatic Disorders Schizophrenia Anxiety Disorders Depression Psychotic Disorders Psychophysiologic Disorders Dementia Anxiety Disorders Dementia

Trials

Pharmacovigilance in Gerontopsychiatric Patients

NCT02374567Phase 3Terminated

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCT02504476Phase 1Completed

KOLs & investigators

Helge Frieling, Prof., MDKOL score 5

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Amgen

company

trial

Pharmacovigilance in Gerontopsychiatric Patients

PHASE3

trial

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

PHASE1

trial

indication

Schizophrenia

indication

Schizophrenia or Schizoaffective Disorder

indication

Depression

indication

Psychosomatic Disorders

indication

KOL

Helge Frieling, Prof., MD

KOL score 5

person